Protein / target

Sialoadhesin

Encoded bySIGLEC1Q9BZZ2Homo sapiensSwiss-Prot

UniProt: Q9BZZ2 Ensembl: ENSG00000088827 HGNC: HGNC:11127 NCBI Gene: 6614

Antibody-tractable

Druggability

UniProt loc high conf

Research papers

Protein at a glance

Biological role

Carbohydrate binding

Strongest disease association

Neoplasms

Via encoding gene SIGLEC1 · Genetic evidence · score 0.55

Research activity

Emerging research

1 papers · latest 2019

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Macrophage-restricted adhesion molecule that mediates sialic-acid dependent binding to lymphocytes, including granulocytes, monocytes, natural killer cells, B-cells and CD8 T-cells.

View complete UniProt function annotation

Macrophage-restricted adhesion molecule that mediates sialic-acid dependent binding to lymphocytes, including granulocytes, monocytes, natural killer cells, B-cells and CD8 T-cells. Plays a crucial role in limiting bacterial dissemination by engaging sialylated bacteria to promote effective phagocytosis and antigen presentation for the adaptive immune response (PubMed:12940982, PubMed:33489013). Mediates the uptake of various enveloped viruses via sialic acid recognition and subsequently induces the formation of intracellular compartments filled with virions (VCCs) (PubMed:28129379). In turn, enhances macrophage-to-T-cell transmission of several viruses including HIV-1 or SARS-CoV-2 (PubMed:28129379, PubMed:34782760). Acts as an endocytic receptor mediating clathrin dependent endocytosis. Preferentially binds to alpha-2,3-linked sialic acid (PubMed:12940982). Binds to SPN/CD43 on T-cells (By similarity). May play a role in hemopoiesis. Plays a role in the inhibition of antiviral innate immune by promoting TBK1 degradation via TYROBP and TRIM27-mediated ubiquitination (PubMed:26358190)

Subcellular location

Cell membraneSecreted

Domains and Gene Ontology detail (29)

Domains & features

Ig-like V-typeIg-like C2-type 1Ig-like C2-type 2Ig-like C2-type 3Ig-like C2-type 4Ig-like C2-type 5Ig-like C2-type 6Ig-like C2-type 7Ig-like C2-type 8Ig-like C2-type 9Ig-like C2-type 10Ig-like C2-type 11Ig-like C2-type 12Ig-like C2-type 13Ig-like C2-type 14Ig-like C2-type 15

Gene Ontology

Cearly endosome
Cextracellular region
Clate endosome
Cmembrane
Cplasma membrane
Fcarbohydrate binding
Fvirion binding
Pcell-cell adhesion
Pcell-matrix adhesion
Pclathrin-dependent endocytosis of virus by host cell
Pinflammatory response
Pnegative regulation of type I interferon production

1709 aa · 183 kDa · 3 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Immune signallingUniProt · GO

View supporting evidence

Immune signalling

·Macrophage-restricted adhesion molecule that mediates sialic-acid dependent binding to l…
·inflammatory response

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene SIGLEC1

Gene-level evidence surfaced through the gene SIGLEC1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Neoplasms

0.61Moderately supported

Genetic evidence dominant · Open Targets 0.33

Ovarian neoplasm

0.47Limited support

Genetic evidence dominant · Open Targets 0.28

Neurodegenerative Diseases

0.28Preliminary

Pathway evidence dominant · Open Targets 0.42 · no direct causal or clinical evidence

Infections

0.14Preliminary

Literature evidence dominant · Open Targets 0.11 · no direct causal or clinical evidence

COVID-19

0.13Preliminary

Literature evidence dominant · Open Targets 0.11 · no direct causal or clinical evidence

View evidence synthesis (5)

NeoplasmsModerately supported

0.61

agreement 0.47–0.75

Genetic79%Literature21%

Open Targets aggregate 0.33 · 2 independent evidence families

Ovarian neoplasmLimited support

0.47

agreement 0.33–0.61

Genetic92%Literature8%

Open Targets aggregate 0.28 · 2 independent evidence families

Neurodegenerative DiseasesPreliminary

0.28

agreement 0.11–0.46

Pathway97%Literature3%

Open Targets aggregate 0.42 · 2 independent evidence families · no direct causal or clinical evidence

InfectionsPreliminary

0.14

agreement 0.00–0.41

Literature100%

Open Targets aggregate 0.11 · 1 independent evidence family · no direct causal or clinical evidence

COVID-19Preliminary

0.13

agreement 0.00–0.40

Literature100%

Open Targets aggregate 0.11 · 1 independent evidence family · no direct causal or clinical evidence

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Neurodegenerative Diseases0.42

Neoplasms0.33

Ovarian neoplasm0.28

Infections0.11

COVID-190.11

Breast Neoplasms0.11

Colorectal Neoplasms0.10

Tractability

Antibodies — Emerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (4)

AB · UniProt loc high confAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMM

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2019

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets.782 cites

Cassetta L · Cancer cell · 2019

Recent

Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets.

Cassetta L · Cancer cell · 2019

Europe PMC papers linked directly to this protein.